JENBURPH · NSE
Jenburkt Pharmaceuticals Limited
₹954
+0.21% (+₹2)
Prev. close
₹952
Volume
1,281
Delivery %
89.2%
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Jenburkt Pharmaceuticals Limited
Jenburkt Pharmaceuticals Limited manufactures and markets pharmaceutical formulations in India and internationally. The company offers therapeutic solutions, such as analgesic and antipyretics, anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants and antacids, aphrodisiac, atopic dermatitis, consumer division, cough and cold, muscle relaxants, neuropathic pain, nutraceuticals, and pain management. It offers its products under the Allerzine, CartiSafe Forte, Crisbo, Eberjen, ECOPROT, Frendacid, Fundu, Glajen-E, GLUCOTROL, HYBRITA, Jenflam, La-Viril, LUMA, Lubtriben, Metmin, Nervega-75, Nervijen P, Nervijen, NOCAL, Numox-625, OJEN, ORNEL, Oxicojen, PANTAZOLE, PIRITEXYL, POWERDOL, Powergesic, Rabera, Topcal-M, Trapidol-D, TREGA, TRIBEN, ZENGLOBIN, ZIX, Zix-MR, Zix-PG 200/75, and Zydol Suspension brand names. The company also exports its products. It serves large government, semi-government institutions, missionary hospitals, and public sector enterprises. Jenburkt Pharmaceuticals Limited was incorporated in 1985 and is based in Mumbai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Ashish Uttam Bhuta
Headquarters
Mumbai
Employees
801
Website
jenburkt.comExchange
View on NSE ↗Key stats
P/E ratio (TTM)
12.8
Dividend yield
2.17%
EPS (TTM)
₹74.35
Beta (5Y monthly)
0.38
Shares float
12.65 L
EPS · quarter ended Jun 2026
₹13.34
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.5% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹109.29 Cr | ₹123.98 Cr | ₹136.14 Cr | ₹141.63 Cr | ₹151.37 Cr | ₹168.31 Cr | |
| EBITDA | ₹24.15 Cr | ₹32.20 Cr | ₹35.42 Cr | ₹37.75 Cr | ₹47.04 Cr | ₹50.00 Cr |
| ₹16.50 Cr | ₹22.30 Cr | ₹24.61 Cr | ₹25.98 Cr | ₹32.06 Cr | ₹34.74 Cr | |
| Diluted EPS | ₹35.96 | ₹48.58 | ₹53.9 | ₹58.86 | ₹72.65 | ₹78.71 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| — | — | ₹142.95 Cr | ₹141.81 Cr | ₹165.10 Cr | ₹196.19 Cr | ₹226.01 Cr | |
| — | — | ₹6.76 Cr | ₹2.93 Cr | ₹0 | ₹3.89 Cr | ₹2.49 Cr | |
| Stockholders' equity | — | — | ₹117.38 Cr | ₹122.39 Cr | ₹144.94 Cr | ₹171.78 Cr | ₹197.04 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Total debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹17.05 Cr | ₹8.12 Cr | ₹27.91 Cr | ₹26.52 Cr | |
| Investing cash flow | — | — | ₹2.62 Cr | ₹-58.04 L | ₹-17.04 Cr | ₹-19.45 Cr |
| — | — | ₹-21.04 Cr | ₹-7.08 Cr | ₹-7.62 Cr | ₹-8.86 Cr | |
| Capital expenditure | — | — | ₹-2.10 Cr | ₹-2.55 Cr | ₹-19.71 Cr | ₹-13.72 Cr |
| End cash position | — | — | ₹3.66 Cr | ₹4.13 Cr | ₹7.36 Cr | ₹5.58 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.44 L Cr | ₹1,852.2 | 37.0 | 5.31 | 13.7% | 0.06 | +11.9% | +13.8% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,619.5 | 87.0 | 15.21 | 15.3% | 0.00 | +12.3% | +63.1% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.28 L Cr | ₹8,889 | 62.5 | 13.48 | 20.5% | 0.90 | +15.7% | +16.6% |
| Lenskart Solutions Limited | ₹1.17 L Cr | ₹680.25 | 177.9 | 13.39 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.13 L Cr | ₹1,399.7 | 33.1 | 3.28 | 11.3% | 0.02 | +2.1% | -7.3% |
| Laurus Labs Limited | ₹1.09 L Cr | ₹2,007 | 100.4 | 20.52 | 16.8% | 0.48 | +22.0% | +123.9% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Max Healthcare Institute Limited | ₹1.02 L Cr | ₹1,014 | 70.0 | 9.47 | 13.4% | 0.32 | +19.0% | -10.9% |
| Dr. Reddy's Laboratories Limited | ₹99,991.95 Cr | ₹1,201 | 30.5 | 2.65 | 11.4% | 0.21 | +3.2% | -5.8% |
| Jenburkt Pharmaceuticals Limited | — | ₹954 | 12.8 | — | 17.6% | 0.01 | +11.2% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.